Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer

Joshua A. Roth, Mark E. Bensink, Paul V. Odonnell, Ephraim J Fuchs, Mary Eapen, Scott D. Ramsey

Research output: Contribution to journalArticle

Abstract

Background: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial. Methods: Consenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives. Conclusion: Novel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.

Original languageEnglish (US)
Pages (from-to)135-144
Number of pages10
JournalJournal of Comparative Effectiveness Research
Volume3
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Bone Marrow Transplantation
Fetal Blood
Cost-Benefit Analysis
Transplantation
Bone Marrow
Tissue Donors
Costs and Cost Analysis
Bone Marrow Cells
Neoplasms
Hematologic Neoplasms
Health Insurance
Health Expenditures
Randomized Controlled Trials
Quality of Life

Keywords

  • blood and bone marrow transplant
  • cost-effectiveness
  • Phase III
  • randomized controlled trial

ASJC Scopus subject areas

  • Health Policy
  • Medicine(all)

Cite this

Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer. / Roth, Joshua A.; Bensink, Mark E.; Odonnell, Paul V.; Fuchs, Ephraim J; Eapen, Mary; Ramsey, Scott D.

In: Journal of Comparative Effectiveness Research, Vol. 3, No. 2, 2014, p. 135-144.

Research output: Contribution to journalArticle

@article{116e5da3c8e54ae7b5aac8df1ba08bf8,
title = "Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer",
abstract = "Background: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial. Methods: Consenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives. Conclusion: Novel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.",
keywords = "blood and bone marrow transplant, cost-effectiveness, Phase III, randomized controlled trial",
author = "Roth, {Joshua A.} and Bensink, {Mark E.} and Odonnell, {Paul V.} and Fuchs, {Ephraim J} and Mary Eapen and Ramsey, {Scott D.}",
year = "2014",
doi = "10.2217/cer.13.95",
language = "English (US)",
volume = "3",
pages = "135--144",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancer

AU - Roth, Joshua A.

AU - Bensink, Mark E.

AU - Odonnell, Paul V.

AU - Fuchs, Ephraim J

AU - Eapen, Mary

AU - Ramsey, Scott D.

PY - 2014

Y1 - 2014

N2 - Background: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial. Methods: Consenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives. Conclusion: Novel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.

AB - Background: BMT CTN 1101 is a Phase III randomized controlled trial evaluating the comparative effectiveness of double unrelated umbilical cord blood (dUCB) versus HLA-haploidentical related donor bone marrow (haplo-BM) donor cell sources for blood or bone marrow transplantation (BMT) in patients with hematologic malignancies. Herein, we present the rationale, design and methods of the first cost-effectiveness analysis to be conducted alongside a BMT trial. Methods: Consenting patients will provide health insurance information to allow calculation of direct medical costs from reimbursement records, and will provide out-of-pocket costs, time costs and health-related quality of life measures through an online survey. These outcomes will inform a cost-effectiveness analysis comparing dUCB and haplo-BM donor cell sources from patient, payer and societal perspectives. Conclusion: Novel approaches may significantly change the cost, outcomes or availability of BMT. The results of this analysis will be the first to provide a comprehensive evaluation of the comparative effectiveness of these approaches from multiple perspectives.

KW - blood and bone marrow transplant

KW - cost-effectiveness

KW - Phase III

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84897837351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897837351&partnerID=8YFLogxK

U2 - 10.2217/cer.13.95

DO - 10.2217/cer.13.95

M3 - Article

C2 - 24645687

AN - SCOPUS:84897837351

VL - 3

SP - 135

EP - 144

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 2

ER -